The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Treatment patterns in HR+/HER2- metastatic breast cancer (MBC) with co-occurring PIK3CA and ESR1 mutations.
 
Jimmitti Teysir
No Relationships to Disclose
 
Sherry Shen
Honoraria - MJH Life Sciences
Research Funding - Merck (Inst); Sermonix Pharmaceuticals (Inst)
 
Charlie White
No Relationships to Disclose
 
Yuan Chen
No Relationships to Disclose
 
Pedram Razavi
Honoraria - Daiichi Sankyo/Astra Zeneca; Pfizer
Consulting or Advisory Role - AstraZeneca; bioTheranostics; Epic Sciences; Guardant Health; Loxo/Lilly; Myriad Genetics; NeoGenomics Laboratories; Novartis; PAIGE.AI; Prelude Therapeutics; SAGA Diagnostics; Tempus
Research Funding - AstraZeneca (Inst); Biovica (Inst); Epic Sciences (Inst); GRAIL (Inst); Guardant Health (Inst); Hologic/Biotheranostics (Inst); Illumina (Inst); Invitae (Inst); Myriad Genetics (Inst); NeoGenomics Laboratories (Inst); Novartis (Inst); Tempus (Inst)
 
Komal Jhaveri
Consulting or Advisory Role - Abbvie; AstraZeneca; Bicycle Therapeutics; Biotheranostics; BluePrint Medicines; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Genentech; Gilead Sciences; Lilly; Novartis; Pfizer; Sanofi; Scorpion Therapeutics; Seagen
Research Funding - AstraZeneca (Inst); Blueprint Medicines (Inst); Context Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); RayzeBio (Inst); Scorpion Therapeutics (Inst); VelosBio/Merck (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche; Gilead Sciences; Intellisphere; Jounce Therapeutics; Lilly; Pfizer; Taiho Pharmaceutical